MedTrace Logo

Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept

NCT02880644 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2023-06-29

No results posted yet for this study

Summary

In patients with macular edema secondary to CRVO, Aflibercept demonstrated efficacy and safety in 2 parallel trials, interventional phase III studies, COPERNICUS study performed in United States and GALILEO study performed in Europe and Asia/Pacific.

With the project of Hermes Study, the first observational study conducted in France in patients with CRVO and treated with aflibercept, we would like to evaluate in real life the monitoring and the use of Aflibercept. The primary objective of this study will also be based on anatomic outcomes. The evolution of retinal ischemia and the degree of non-retinal perfusion will be particularly evaluated by using ultra wide field angiography technology.

Conditions

  • Retinal Vein Occlusion

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Association Clinique Thérapeutique Infantile du val de Marne

    collaborator OTHER

  • Centre Hospitalier Intercommunal Creteil

    lead OTHER

Principal Investigators

  • Agnès GLACET-BERNARD, MD · Centre Hospitalier Intercommunal Créteil

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-26
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02880644 on ClinicalTrials.gov